# Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.

- **DOI:** [10.1186/s13195-026-02082-9](https://doi.org/10.1186/s13195-026-02082-9)
- **Rating:** Sound (3.3 out of 5)
- **Verdict:** A useful first-in-human vaccine study establishes immunogenicity and detailed safety surveillance, but unresolved ARIA-H interpretation prevents a reassuring benefit-risk conclusion.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs13195-026-02082-9

## Key claims

1. ALZ‑101 was not associated with clear safety signals
   - Support: Tentative
   - Type: Primary finding
   - Basis: small safety sample and an ARIA-H count exceeding the paper's mean literature benchmark
   - Location: Abstract; Conclusions
2. ALZ‑101 induced robust Aβ‑specific IgG responses in nearly all vaccinated participants, with classical primary/booster kinetics and high responder rates at all dose levels.
   - Support: Tentative
   - Type: Secondary
   - Basis: revised ELISA cut-off, placebo false positives, and inconsistent responder arithmetic qualify the reported response rate
   - Location: Abstract; Results, Immunogenicity
3. No statistically significant between‑group differences were detected for pre‑specified CSF biomarkers or cognitive and functional outcomes versus placebo in the randomised phase.
   - Support: Tentative
   - Type: Secondary
   - Basis: the randomized phase was small and Results report a nominal Week 20 ADCOMS difference
   - Location: Abstract; Results, Exploratory CSF Biomarkers and Cognitive and Functional Assessments
4. Over longer follow‑up in Part B, participants initially randomised to ALZ‑101 showed numerically smaller increases in CSF neurofilament light chain (NfL) and tau and a flatter ADCOMS trajectory than those initially on placebo, but these differences were not statistically significant.
   - Support: Supported
   - Type: Secondary
   - Basis: reported numerical patterns are descriptive, but the completer extension lacked a concurrent placebo group
   - Location: Abstract; Results, Part B analyses, Figures 4–6

## Strengths

- **Detailed MRI and safety surveillance** Scheduled 3T MRI, central blinded reads, prespecified ARIA definitions, post-dose observation, and DSMB review provide a substantial safety-monitoring framework. Tables 2 and 3 report participant-level denominators, severity, serious events, and ARIA patterns.
  - Dimension: methodological rigour
  - Location: Methods, MRI Scans and Study Assessments; Tables 2–3
- **Genuine first-in-human clinical contribution** The trial provides initial human safety and immunogenicity observations for an active vaccine based on a stabilized oligomeric Aβ42 derivative. This is useful for deciding whether and how to proceed to a larger controlled study.
  - Dimension: contribution
  - Location: Abstract; Introduction, final paragraph; Methods, Study Design
- **Exploratory analyses usually identified clearly** The statistical methods state that clinical outcomes were exploratory and nominal, while the ADNI comparison is expressly described as non-prespecified and hypothesis-generating. The Discussion also states that it cannot establish efficacy.
  - Dimension: positioning
  - Location: Methods, Statistical Analysis and Exploratory External-Comparator Analysis; Discussion, ADCOMS comparison

## Limitations

- **Safety conclusion understates ARIA-H findings** Nine participants developed ARIA-H, and the Discussion's Poisson analysis places the observed count above the mean literature benchmark. This is not adequately reconciled with the Abstract and Conclusions stating that there were no clear safety signals.
  - Dimension: reporting
  - Location: Abstract; Table 3; Discussion, ARIA-H benchmark analysis; Conclusions
- **Immunogenicity measurement and counts conflict** The original ELISA cut-off was judged inaccurate and replaced with an in-study value after high natural-antibody signals and placebo false positives appeared. The reported “five of six (93.3%)” responder count is also arithmetically inconsistent, and later reclassification complicates the stated 90% rate.
  - Dimension: methodological rigour
  - Location: Methods, Secondary Outcomes; Results, Immunogenicity; Discussion, responder classification
- **Extension cannot establish disease modification** Part B admitted Part A1 completers, placed everyone on active treatment, and disclosed that active treatment was being administered. Cognitive and biomarker stabilization claims therefore rely on selected participants, unblinded assessments, and non-prespecified historical comparisons.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and External-Comparator Analysis; Results, Exploratory CSF Biomarkers and Cognitive Assessments

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - No statistically significant between‑group differences were detected for pre‑specified CSF biomarkers or cognitive and functional outcomes versus placebo in the randomised phase: "No statistically significant between‑group differences were detected for pre‑specified CSF biomarkers or cognitive and functional outcomes versus placebo in the randomised phase." (Abstract, Results) vs "the 125 µg ALZ-101 group showed a -0.10 difference (95% CI: -0.20 to 0.00; P = 0.040) relative to placebo" (Results, Exploratory cognitive and functional assessments). The reported nominal ADCOMS P = 0.040 is below 0.05 and therefore constitutes an exception to the Abstract's blanket statement, notwithstanding its exploratory status. → Not supported by the paper's own data
  - ALZ‑101 induced robust Aβ‑specific IgG responses in nearly all vaccinated participants, with classical primary/booster kinetics and high responder rates at all dose levels: "in the ALZ-101 400 µg group (Part A2), five of six (93.3%) participants were responders." (Results, Immunogenicity) vs "1/6 (17%) in the 400 µg group" (Discussion, final responder classification). Five responders among six participants gives 100 × 5/6 = 83.3%, consistent with one non-responder among six rather than the reported 93.3%. → Conclusion holds
  - ALZ‑101 induced robust Aβ‑specific IgG responses in nearly all vaccinated participants, with classical primary/booster kinetics and high responder rates at all dose levels: "Of the 32 enrolled participants, 31 received the study drug (one placebo participant in Part A1 withdrew before entering Part B), with 29 meeting the predefined responder criteria." (Discussion, immunogenicity responder classification) vs "Overall, three participants were thus ultimately classified as non‑responders:" (Discussion, immunogenicity responder classification). After the additional apparent responder is reclassified, 31 actively treated participants minus three final non-responders gives 28 final responders, or 90.3%, rather than retaining the earlier count of 29. → Conclusion holds
- **Reporting and transparency:** Noted. Registration followed the start of enrollment by 167 days. The ELISA cut-point replacement is disclosed but its numerical effect cannot be reconstructed, and the title does not distinguish the randomized phase from the nonrandomized phases.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean
  - 96 references in manuscript
  - 96 of 96 checkable references found in an index
  - 1 DOI points to a different paper:
    - #71 Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol., van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356-60. 10.1212/01.wnl.0000210535.20297.ae 16682667 (DOI resolves to: “Prevalence and severity of microbleeds in a memory clinic setting” — Cordonnier, 2006 (Neurology)) https://doi.org/10.1212/01.wnl.0000210535.20297.ae
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
